Shots:
- The first co-administration descriptive study evaluates Fluzone high-dose quadrivalent vaccine + Moderna’s COVID-19 mRNA booster dose (100 mcg dose) in 300 patients aged ≥65yrs. who received two doses of a COVID-19 mRNA vaccine as primary vaccination 5mos. prior to enrolment
- The results showed that both vaccines had similar immunogenicity responses along with similar safety and tolerability profile compared to each vaccine administered individually. The results will be published in 2021
- Fluzone high-dose quadrivalent is also licensed under the brand name Efluelda in the EU for adults aged ≥60yrs. Moderna’s application for a booster indication is currently under the US FDA’s review
Click here to read full press release/ article | Ref: Sanofi | Image: Evaluate Pharma
The post Sanofi Reports Interim Results of Fluzone High-Dose Quadrivalent Vaccine + COVID-19 mRNA Booster Dose in First Descriptive Study for COVID-19 first appeared on PharmaShots.
